BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 14630271)

  • 1. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
    Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
    Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial.
    Wu KL; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Zhao S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1345-50. PubMed ID: 14630272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
    Kepka L; Tyc-Szczepaniak D; Bujko K
    J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
    Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
    BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
    Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation for non-small cell lung cancer using conformal radiation therapy.
    Robertson JM; Ten Haken RK; Hazuka MB; Turrisi AT; Martel MK; Pu AT; Littles JF; Martinez FJ; Francis IR; Quint LE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1079-85. PubMed ID: 9169816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
    Wurstbauer K; Deutschmann H; Kranzinger M; Merz F; Rahim H; Sedlmayer F; Kogelnik HD
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):333-41. PubMed ID: 10760428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
    Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.